Company Profile · Healthcare

Asymchem Laboratories Tian Jin Co Ltd

002821 · Shenzhen
Industry
Pharma Manufacturing Outsourcing (CDMO)
Exchange
Shenzhen
Country
China
Employees
10,617
Website
www.asymchem.com.cn
Current Price
¥123.82
Live · Jun 22, 2026
Fair Buy
≤ ¥70
Margin-of-safety entry
Baillie Growth Score
51/100
Medium
Intrinsic Value · Three-Tier Range Current price ¥123.82 Live · Within the fair intrinsic-value range

Composite valuation range · conservative ¥68–¥70 / fair ¥98–¥132 / optimistic ¥161–¥176. At ¥123.82, Within the fair intrinsic-value range.

At publication ¥128.7 (Jun 24, 2026)

About the company

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Financial snapshot
Market capCN¥46.81B
Revenue (TTM)CN¥6.93B
EBITDACN¥1.66B
Profit margin16.02%
ROE6.28%
P/E (TTM)41.72
Forward P/E0
EPSCN¥3.11
Dividend yield1.03%
52-week rangeCN¥82.27 – CN¥132.98

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Research on this stock
Asymchem Laboratories (Tianjin) Co., Ltd.
002821 · Shenzhen
Hold
Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success

Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.

Pharma Manufacturing Outsourcing (CDMO) Baillie 51 Jun 24, 2026